

# Lothar Seefried

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7733546/publications.pdf>

Version: 2024-02-01

49  
papers

1,492  
citations

331259

21  
h-index

344852

36  
g-index

76  
all docs

76  
docs citations

76  
times ranked

1860  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Diagnostics in Routine Osteological Assessment of Adult Low Bone Mass Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3048-e3057.	1.8	12
2	Lower limb bone geometry in adult individuals with X-linked hypophosphatemia: an observational study. <i>Osteoporosis International</i> , 2022, 33, 1601-1611.	1.3	8
3	Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. <i>Nature Reviews Endocrinology</i> , 2022, 18, 366-384.	4.3	42
4	Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. <i>Osteoporosis International</i> , 2021, 32, 7-22.	1.3	41
5	Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. <i>Bone</i> , 2021, 142, 115664.	1.4	15
6	Bone mineral density and fracture risk in adult patients with hypophosphatasia. <i>Osteoporosis International</i> , 2021, 32, 377-385.	1.3	27
7	Differential impact of osteoporosis, sarcopenia and obesity on physical performance in aging men. <i>Endocrine Connections</i> , 2021, 10, 256-264.	0.8	3
8	Sarcopenia and Malnutrition Screening in Female Osteoporosis Patients – A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2344.	1.0	2
9	Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1334-1343.	1.0	3
10	Relevant genetic variants are common in women with pregnancy and lactation-associated osteoporosis (PLO) and predispose to more severe clinical manifestations. <i>Bone</i> , 2021, 147, 115911.	1.4	14
11	Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. <i>Osteoporosis International</i> , 2021, 32, 2505-2513.	1.3	11
12	Challenges in the management of tumor-induced osteomalacia (TIO). <i>Bone</i> , 2021, 152, 116064.	1.4	27
13	Feasibility of simple exercise interventions for men with osteoporosis – A prospective randomized controlled pilot study. <i>Bone Reports</i> , 2021, 15, 101099.	0.2	1
14	Genetics and future therapy prospects of fibrodysplasia ossificans progressiva. <i>Medizinische Genetik</i> , 2020, 31, 391-396.	0.1	2
15	Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance. <i>Journal of Bone Oncology</i> , 2020, 25, 100323.	1.0	5
16	Physical Function and Health-Related Quality of Life in Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia. <i>JBMR Plus</i> , 2020, 4, e10395.	1.3	26
17	Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2171-2178.	3.1	38
18	Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 212.	1.2	22

#	ARTICLE	IF	CITATIONS
19	Penetration of topical diclofenac into synovial tissue and fluid of osteoarthritic knees: a multicenter, randomized, placebo-controlled, pharmacokinetic study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094308.	1.2	9
20	Mineral Intake and Clinical Symptoms in Adult Patients with Hypophosphatasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2982-e2992.	1.8	7
21	Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS). <i>Journal of Bone and Mineral Research</i> , 2020, 37, 420-427.	3.1	9
22	Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 80.	0.8	69
23	Primary Osteoporosis Is Not Reflected by Disease-Specific DNA Methylation or Accelerated Epigenetic Age in Blood. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 356-361.	3.1	33
24	Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia "not atypical at all. <i>Osteoporosis International</i> , 2018, 29, 1815-1825.	1.3	44
25	Physical contact between mesenchymal stem cells and endothelial precursors induces distinct signatures with relevance to the very early phase of regeneration. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 9122-9140.	1.2	3
26	BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1496-1504.	3.1	107
27	Dissection of mechanoresponse elements in promoter sites of the mechanoresponsive CYR61 gene. <i>Experimental Cell Research</i> , 2017, 354, 103-111.	1.2	7
28	High Prevalence of Vitamin D Deficiency in Patients With Bone Marrow Edema Syndrome of the Foot and Ankle. <i>Foot and Ankle International</i> , 2017, 38, 760-766.	1.1	42
29	Epidermal growth factor as a mechanosensitizer in human bone marrow stromal cells. <i>Stem Cell Research</i> , 2017, 24, 69-76.	0.3	18
30	Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 4-17.	0.5	84
31	Distribution of Constituents and Metabolites of Maritime Pine Bark Extract (Pycnogenol®) into Serum, Blood Cells, and Synovial Fluid of Patients with Severe Osteoarthritis: A Randomized Controlled Trial. <i>Nutrients</i> , 2017, 9, 443.	1.7	32
32	Cellular pharmacodynamic effects of Pycnogenol® in patients with severe osteoarthritis: a randomized controlled pilot study. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 537.	3.7	25
33	Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. <i>Journal of Clinical Investigation</i> , 2017, 127, 2148-2158.	3.9	64
34	Efficacy and safety of whole body vibration in maintenance hemodialysis patients - A pilot study. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2017, 17, 268-274.	0.1	7
35	Asfotase alfa: Enzyme replacement for the treatment of bone disease in hypophosphatasia. <i>Drugs of Today</i> , 2016, 52, 271.	0.7	21
36	Recombinant Enzyme Replacement Therapy in Hypophosphatasia. <i>Sub-Cellular Biochemistry</i> , 2015, 76, 323-341.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Diagnostic Findings and Treatment in a 51-Year-Old Woman With Oncogenic Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 385-386.	1.8	2
38	Clinical Aspects of Hypophosphatasia: An Update. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 60-70.	1.3	52
39	The Transcriptional Profile of Mesenchymal Stem Cell Populations in Primary Osteoporosis Is Distinct and Shows Overexpression of Osteogenic Inhibitors. PLoS ONE, 2012, 7, e45142.	1.1	158
40	Trace Elements and Bone. , 2011, , 81-86.		2
41	BMP12 and BMP13 gene transfer induce ligamentogenic differentiation in mesenchymal progenitor and anterior cruciate ligament cells. Cytotherapy, 2010, 12, 505-513.	0.3	70
42	Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochemical and Biophysical Research Communications, 2010, 394, 755-759.	1.0	74
43	A small scale cell culture system to analyze mechanobiology using reporter gene constructs and polyurethane dishes. , 2010, 20, 344-355.		20
44	FGF23 is a putative marker for bone healing and regeneration. Journal of Orthopaedic Research, 2009, 27, 1141-1146.	1.2	41
45	Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone, 2009, 44, 858-864.	1.4	64
46	Biology of Mesenchymal Stem Cells. Current Rheumatology Reviews, 2008, 4, 148-154.	0.4	3
47	Influence of hormones on osteogenic differentiation processes of mesenchymal stem cells. Expert Review of Endocrinology and Metabolism, 2007, 2, 59-78.	1.2	2
48	Frakturheilung bei Osteoporose. Osteologie, 2007, 16, 71-84.	0.1	10
49	Aldo Castellani " an Appraisal of his Life and Oeuvre Aldo Castellani " sein Leben und sein Werk. Mycoses, 1989, 32, 391-397.	1.8	5